Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 39 for “"Chronic Lymphocytic Leukemia"”.
-
Array based genetic profiling of chronic lymphocytic leukemia
… no common genetic defect has been described in chronic lymphocytic leukemia (CLL), recurrent genomic aberrations (i.e. deletions of chromosome 11q, 13q, 17p and trisomy 12) are important for prognostication. Deletion of 13q as single aberration is associated with the best prognosis, whereas …
-
CD200: A Novel Therapeutic Target for Chronic Lymphocytic Leukemia
… of CD200, a potent immunoregulatory molecule, in Chronic Lymphocytic Leukemia. We showed that functional blockade of CD200 on lymphoma cells or primary CLL cells, both of which express CD200 at high levels, augmented cytotoxic killing of these cells by effector CD8+ T cells in vitro. We also …
-
Understanding the biology of CD180 in chronic lymphocytic leukemia
… of B cells, but differentially expressed on chronic lymphocytic leukaemia (CLL) cells from different patients. The loss of CD180 in CLL indicates that the receptor somehow confers a survival advantage for the tumour. In support of this, we found that CD180 expression was enriched in CLL cases …
-
The role of type I interferon in chronic lymphocytic leukemia
… of this thesis were to study the role of IFN in chronic lymphocytic leukemia (CLL), the most common adult leukemia. CLL cells were found to exhibit the capacity to both produce and respond to autocrine IFN. Leukemic cells from patients with clinically aggressive disease expressed higher IFN …
-
Ldoc1, A Novel Biomarker of Prognosis In Chronic Lymphocytic Leukemia
<p>In chronic lymphocytic leukemia (CLL), one of the best predictors of outcome is the somatic mutation status of the immunoglobulin heavy chain variable region (IGHV) genes. Patients whose CLL cells have unmutated IGHV genes have a median survival of 8 years; those with mutated IGHV genes have a …
-
Subclonal Evolution of Chronic Lymphocytic Leukemia After Allogeneic T Cell Therapies
<p><strong>Subclonal evolution of chronic lymphocytic leukemia after allogeneic T-cell therapies</strong></p> <p>Haven Garber, MD</p> <p>Advisory Professor: Jeffrey Molldrem, MD</p> <p>Intratumoral genetic heterogeneity describes the molecular differences among subclones within a tumor and is a …
-
Investigating Apoptosis Pathway In Chronic Lymphocytic Leukemia: Stromal Influence and Therapeutic Activation
<p>Chronic lymphocytic leukemia (CLL) is a B-cell malignancy. High levels of Bcl-2 and IAP family proteins are responsible for apoptotic-resistance and accumulation of mature CLL lymphocytes in bone-marrow, lymph nodes and peripheral blood. Besides pro-survival proteins, supporting stromal cells as …
-
GENOMIC AND EPIGENETIC APPROACHES IN THE CLINICAL AND PROGNOSTIC STRATIFICATION OF CHRONIC LYMPHOCYTIC LEUKEMIA
Chronic lymphocytic leukemia (CLL) is characterized by highly clinical heterogeneity; the identification of factors that could predict the clinical course of early-stage CLL represents a crucial objective in this malignancy. The aim of the study is to identify novel biological markers that may be …
-
Characterization of Tcl1-Tg:P53-/- Mice That Resemble Human Chronic Lymphocytic Leukemia With 17P-Deletion
<p>Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the United Statesand Europe. CLL patients with deletion of chromosome 17p, where the tumor suppressor p53 gene is located, often develop a more aggressive disease with poor clinical outcomes. However, the underlying …
-
Targeting The Redox System to Overcome Mechanisms of Drug Resistance In Chronic Lymphocytic Leukemia
<p>Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia diagnosed in Western countries and is characterized by clonal expansion of B cells. The clinical course of CLL is diverse and nearly 50% of patients present with chromosomal abnormalities. Deletion of the short arm on …
-
Actions of Pi3K-Delta Inhibitor, Idelalisib, and Its Combination With Bendamustine In Chronic Lymphocytic Leukemia
… tumors and in hematologic malignancies.</p> <p>Chronic lymphocytic leukemia (CLL) is driven by B-cell receptor (BCR) signaling that promotes B-cell proliferation and survival. PI3K is a critical node in BCR pathway and PI3Kδ has a pivotal role in B-cell development and maintenance and this …
-
Therapeutic Vulnerabilities of Venetoclax Resistant Chronic Lymphocytic Leukemia and Novel Treatment Strategies Targeting BCL2/BCL-XL
… major advancements in the management of chronic lymphocytic leukemia (CLL), drug resistance remains a major challenge. CLL resistant to venetoclax (VEN) have limited available therapeutic options, especially when the leukemic cells have dysfunctional p53 and have relapsed on Bruton’s …
-
Role of Gsh Metabolism In Mediating Stromal-Leukemia Interaction and Promoting Cell Survival and Drug Resistance In Chronic Lymphocytic Leukemia
<p>Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the western countries. The interaction between CLL cells and the bone marrow stromal environment is thought to play a major role in promoting the leukemia cell survival and drug resistance. My dissertation works proved a …
-
“Watch and Wait” - Examining the potential impact of uncertainty in illness on the mental health of individuals with Chronic Lymphocytic Leukemia and Low Grade Lymphomas
Chronic lymphocytic leukemia (CLL) and non-localised low grade or indolent lymphomas (LGL) are two of the common cancers that individuals are diagnosed with in the UK. Both of these chronic illnesses are considered slow growing and these individuals are often diagnosed when one is not exhibiting …
-
Development and study of a monoclonal antibody to the human HLA-class II invariant chain
… to the peripheral blood cells of a patient with chronic lymphocytic leukemia (CLL). It was initially hoped that such an antibody, if directed against an idiotypic determinant on the malignant B-cell surface, may prove to be useful therapeutically by virtue of its specificity and limited …
-
From Oncogenesis to Immunotherapy: Mathematical Modeling of Heterogeneous Cancers
… with substantial mutational heterogeneity: chronic lymphocytic leukemia (CLL) and mismatch-repair deficient colorectal cancer (MMR-D CRC). First, to study the progression of CLL into an aggressive lymphoma, Richter’s Syndrome (RS), we analyze data from a recent mouse model and utilize a …
-
Exploiting biological pathways to infer temporal gene interaction models
… and provides a clinical application, as B cell chronic lymphocytic leukemia (B-CLL) is believed to be related to BCR response. In this work, we infer population-dependent gene networks of temporal interaction within the BCR signaling pathway. We develop simple statistical models that capture the …
-
Cll Metabolism Is Regulated By Prognostic Factors, Modulated By Stroma and Abrogated By Pi3K Inhibition
<p>Metabolism of chronic lymphocytic leukemia (CLL), a disease characterized by the relentless accumulation of mature B cells has been little explored. Bone marrow stromal cells provide a survival benefit to CLL cells, in part through PI3K/AKT pathway. Compared with proliferative B-cell lines, …
Page 1 of 2